Company Overview and News
I have been banging the drum about a market correction, but I suppose I just might croak waiting for one. The bottom line is that I have been wrong or early. Being early is still being wrong, folks, and I won't hide from the facts.
The Finance sector, which has been in the spotlight since the U.S. Presidential elections in November 2016, reported impressive first-quarter 2018 results. Per the latest Earnings Preview, the S&P 500 finance stocks recorded 24.7% year-over-year earnings improvement. This was mainly driven by favorable macroeconomic factors, higher interest rates, decent loan and deposit growth, and lower tax rates.
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.
SPRINGFIELD, IL / ACCESSWIRE / May 7, 2018 / Horace Mann Educators Corporation (NYSE: HMN) today announced the appointment of industry veteran Heather J. Wietzel, IRC, as Vice President, Investor Relations.
The quarterly profit was impacted by a drop in investment gains, in spite of the improvement in underwriting margins.
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 5/2/18.
There could be some decent values around but I think there will be better bargains soon.
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,V M,#7!E+UA2968O5ULQ(#(@,5T^/G-T('$UUD,3(P,,T!*&!B9_C/[email protected]\08 "07 [email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.#X^
Cincinnati Financial Corporation (CINF - Free Report) reported first-quarter 2018 operating income of 72 cents per share, which missed the Zacks Consensus Estimate of 82 cents by 12.2%. Nonetheless, the bottom line improved 22% year over year, mainly on higher revenues and a solid segmental performance.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET